In September 2013 the Scottish Government launched the first national shingles immunisation campaign using Zostavax, which is a live attenuated vaccine. It is derived from the Oka strain of VZV and has significantly higher antigen content than the varicella vaccine.
In the first year of the programme, the vaccine was offered to non-immunocompromised adults aged 70 years and also rolled out as part of an ongoing in a catch-up programme to 79-year-olds.
- The annual uptake for Scotland, based on submissions from approximately 95% of the practices, was 59.7% for the routine cohort (those aged 70 years on 1 September 2013) and ranged from 51.2% in to 66.8% across the NHS boards.
Annual uptake for the catch-up cohort (those aged 79 years on 1 September 2013) was 55.6% and ranged from 47% to 65% across the NHS boards.